La vendita allo scoperto per Avantis International Small Cap Value ETF dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Avantis International Small Cap Value ETF. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Avantis International Small Cap Value ETF (ARCA:AVDV), Report sulle vendite allo scoperto

Industrials

Financial Services

Consumer Cyclical

Basic Materials

Energy

Technology

Consumer Defensive

Real Estate

Healthcare

Communication Services

Other

Utilities

Consumer Staples

The fund invests primarily in a diverse group of non-U.S. small cap value companies across market sectors, industry groups, and countries. The fund seeks to achieve higher expected returns by selecting securities of companies with higher profitability and value characteristics, as well as smaller market capitalizations relative to others within the fund's small cap investment universe.

Marks & Spencer Group Plc

Swissquote Group Holding Sa

Fujikura Ltd

Saipem Spa Common Stock Eur 0

Pacific Basin Shipping Ltd Common Stock Usd.01

Vallourec S.A.

Capital Power Corp.

Bankinter Sa

Avantis International Small Cap Value ETF

Earnings

Earnings Beats

News

Marcus & Millichap Earlier Reported Q3 EPS $(0.14) Beats $(0.19) Estimate, Sales $168.51M Beat $160.90M Estimate

Raymond James analyst Robert Dodd downgrades WhiteHorse Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHF#NASDAQ">WHF</a>) from Outperform to Market Perform.

Downgrades

Analyst Ratings

Raymond James Downgrades WhiteHorse Finance to Market Perform

Earnings Misses

Brookfield Bus Partners Q3 2024 EPS $1.39, Revenues $9.232B

RBC Capital analyst Leonid Timashev initiates coverage on Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Outperform rating and announces Price Target of $80.

Price Target

Initiation

CYTK

RBC Capital Initiates Coverage On Cytokinetics with Outperform Rating, Announces Price Target of $80

Adjusted EBITDA is expected to be in the range of $880 million to $920 million. Capital expenditures are expected to be approximately $250 million.

Guidance

Advanced Drainage Systems Cuts FY25 Net Sales Outlook From $2.925B - $3.025B To $2.900B - $2.975B,  Est $2.985B

Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) said on Thursday after market close that it is on track to turn a gross profit in the fourth quarter despite a<a href="https://www.benzinga.com/news/24/10/41223011/rivians-production-guidance-cut-spurred-by-miscommunication-with-atlanta-based-supplier-resulting-in"> production disruption flagged earlier this year.</a>
What Happened: The EV maker on Thursday also reaffirmed its 2024 delivery outlook of 50,5000 to 52,000 vehicles for the full year, helping relieve investor worries.
Rivian cut its annual production forecast last month by as much as 18% to between 47,000 and 49,000 electric vehicles, citing production disruption owing to a component shortage. However, the production disruption will not seemingly impact the company&#8217;s delivery targets for the year. 
For the third quarter, the EV startup <a href="https://www.benzinga.com/news/earnings/24/11/41825787/rivian-q3-earnings-highlights-revenue-eps-miss-ceo-confident-in-q4-gross-profit-r2-being-fundamenta">reported revenue of $874 million</a>, which missed a Street consensus estimate of $1.00 billion, and a loss of 99 cents per share, missing a Street consensus loss of 92 cents per share. 
The company also announced a five-year strategic supply agreement for batteries with&nbsp;LG Energy Solutions for its R2 SUV, slated for launch in the first half of 2026. 
Why It Matters: Rivian produced 13,157 vehicles in the third quarter and delivered 10,018 vehicles. Currently, the company has only two vehicles in production- the R1T truck and the R1S SUV with a starting price of around $70,000. 
The company is looking to expand its total addressable market with the R2 SUV expected to be priced around $45,000, in the same price range as Tesla Inc&#8217;s best-selling Model Y SUV. 
The company is also planning to start deliveries of its<a href="https://www.benzinga.com/news/24/03/37552684/rivian-almost-catches-up-to-teslas-ev-lineup-with-new-r2-r3-but-theres-no-cybertruck-fighter-yet"> R3 crossover after the R2.</a> The crossover is expected to be priced lower than the R2 SUV but it is unclear whether the R3's price will undercut the Tesla Model 3 or remain within the same range.
Price Action: Rivian shares closed up 3.35% at $10.04 on Thursday. The stock is down 52.4% year-to-date, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. 
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41803756/xpeng-flying-car-can-be-mastered-in-3-hours-says-company-chairman" target="_blank" rel="noreferrer noopener">XPeng Flying Car Can Be Mastered In 3 Hours, Says Company Chairman</a></li>
</ul>
Image via Shutterstock

Tech

General

RIVN

Rivian Says It Is On Track For 2024 Delivery Targets Despite Production Challenges

Hippo Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIPO#NYSE">HIPO</a>) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.95) by 64.21 percent. The company reported quarterly sales of $95.500 million which beat the analyst consensus estimate of $94.064 million by 1.53 percent. This is a 65.51 percent increase over sales of $57.700 million the same period last year.

HIPO

Hippo Holdings Q3 2024 GAAP EPS $(0.34) Beats $(0.95) Estimate, Sales $95.500M Beat $94.064M Estimate

Macquarie analyst Paul Golding downgrades Planet Fitness (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLNT#NYSE">PLNT</a>) from Outperform to Neutral and raises the price target from $91 to $99.

PLNT

Macquarie Downgrades Planet Fitness to Neutral, Raises Price Target to $99

Fiscal 2025 Outlook
The Company's outlook for 2025 was updated as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">(as of November 8, 2024)</td>
<td colspan="1" rowspan="1">Updated Fiscal 2025 Guidance</td>
<td colspan="1" rowspan="1">Previous Guidance</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Sales</td>
<td colspan="1" rowspan="1">$200 million to $210 million</td>
<td colspan="1" rowspan="1">$200 million to $210 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Gross Margin</td>
<td colspan="1" rowspan="1">23% to 24% of sales</td>
<td colspan="1" rowspan="1">22% to 23% of sales</td>
</tr>
<tr>
<td colspan="1" rowspan="1">SG&amp;A expense (including amortization)(1)</td>
<td colspan="1" rowspan="1">17.0% to 18.0% of sales</td>
<td colspan="1" rowspan="1">16.5% to 17.5% of sales</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA(2)</td>
<td colspan="1" rowspan="1">$18.0 million to $21.0 million</td>
<td colspan="1" rowspan="1">$16.5 million to $19.5 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Effective Tax Rate</td>
<td colspan="1" rowspan="1">20% to 22%</td>
<td colspan="1" rowspan="1">20% to 22%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Capital Expenditures</td>
<td colspan="1" rowspan="1">$13.0 million to $18.0 million</td>
<td colspan="1" rowspan="1">$10.0 million to $15.0 million</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">(1)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Includes approximately $6.5 million to $7.5 million of BN supplemental performance bonus, equity-based compensation, and ERP conversion costs included in SG&amp;A expense.</td>
</tr>
</tbody>
</table>
</figure>

Graham Reaffirms 2025 Net Sales Outlook Of $200M-$210M Vs. $205.40M Est.; Raises Gross Margin Guidance To 23%-24% From 22%-23% And Adj. EBITDA To $18M-$21M From $16.5M-$19.5M

Embraer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ERJ#NYSE">ERJ</a>) reported quarterly earnings of $1.20 per share which beat the analyst consensus estimate of $0.60 by 100 percent. The company reported quarterly sales of $1.69 billion which beat the analyst consensus estimate of $1.59 billion by 6.34 percent. This is a 31.73 percent increase over sales of $1.28 billion the same period last year.

Embraer-Empresa Brasileira De Aeronautica

Embraer Q3 2024 Adj EPS $1.20 Beats $0.60 Estimate

Keybanc analyst Scott Schoenhaus upgrades Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) from Sector Weight to Overweight and announces $70 price target.

Upgrades

DOCS

Keybanc Upgrades Doximity to Overweight, Announces $70 Price Target

DCBO

Docebo Raises FY24 Outlook: Sees Total Revenue Growth Of Approximately 19.5% (Prior View: 18.0%-19.0%), Adjusted EBITDA As A Percentage Of Total Revenue Of Approximately 15.5%

Advanced Drainage Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMS#NYSE">WMS</a>) reported quarterly earnings of $1.70 per share which missed the analyst consensus estimate of $1.90 by 10.53 percent. This is a 0.58 percent decrease over earnings of $1.71 per share from the same period last year. The company reported quarterly sales of $782.61 million which missed the analyst consensus estimate of $822.35 million by 4.83 percent. This is a 0.31 percent increase over sales of $780.22 million the same period last year.

Advanced Drainage Systems Q2 2025 Adj EPS $1.70 Misses $1.90 Estimate, Sales $782.61M Miss $822.35M Estimate

Management expects subscription revenue to grow about two percentage points higher than overall company revenue while professional services revenue to be down sequentially from Q3.

Docebo Sees Q4 Revenues Of $56M-$56.2M Vs. $56.02M Estimate; Adjusted EBITDA Margin Of 16.5%-16.7%

Raymond James analyst Justin Jenkins downgrades EnLink Midstream (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENLC#NYSE">ENLC</a>) from Outperform to Market Perform.

ENLC

Raymond James Downgrades EnLink Midstream to Market Perform

Full-year 2024 Adjusted EBITDA Guidance Remains Unchanged At A Range Of $220 Million To $240 Million.

FTRE

Fortrea Narrows FY24 Revenue Guidance From $2.70B - $2.75B To $2.70B - $2.725B, Est $2.697B

2024 Financial Guidance
Management reiterates its full year 2024 guidance:
<ul>
<li>Anticipated Total Net Revenues expected to be between $87 million and $95 million;</li>
<li>Anticipated Operating Expenses expected to remain between $115 million and $120 million;</li>
<li>Anticipated Total Annual Cash Investment expected to remain between $15 million and $20 million; and</li>
<li>Cash and Cash Equivalents anticipated to continue to support operations as currently planned into 2027.</li>
</ul>

Biotech

Health Care

YMAB

Y-mAbs Anticipates 2024 Total Net Revenues Of $87M-$95M Vs. Consensus Of $91.67M

Atmus Filtration Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATMU#NYSE">ATMU</a>) raises FY2024 Adj EPS guidance from $2.15-2.40 to $2.35-2.50 vs $2.20 analyst estimate. Raises FY2024 sales outlook from $1.63 billion-1.68 billion to $1.65 billion-1.68 billion vs $1.66 billion estimate.

ATMU

Atmus Filtration Techs Raises FY2024 Adj EPS Guidance from $2.15-2.40 to $2.35-$2.50 vs $2.20 Est; Raises FY2024 Sales Guidance from $1.63B-$1.68B to $1.65B-$1.68B vs $1.66B Est

Atmus Filtration Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATMU#NYSE">ATMU</a>) reported quarterly earnings of $0.61 per share which beat the analyst consensus estimate of $0.49 by 24.49 percent. This is a 17.31 percent increase over earnings of $0.52 per share from the same period last year. The company reported quarterly sales of $403.70 million which beat the analyst consensus estimate of $403.41 million by 0.07 percent. This is a 1.89 percent increase over sales of $396.20 million the same period last year.

Atmus Filtration Techs Q3 Adj $0.61 Beats $0.49 Estimate, Sales $403.70M Beat $403.41M Estimate

Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) reported quarterly losses of $(0.16) per share which met the analyst consensus estimate. This is a 11.11 percent increase over losses of $(0.18) per share from the same period last year. The company reported quarterly sales of $18.46 million which missed the analyst consensus estimate of $23.26 million by 20.64 percent. This is a 9.74 percent decrease over sales of $20.45 million the same period last year.

Comments

Avantis International Small Cap Value ETF

Vendite allo scoperto

Avantis International Small Cap Value ETF (ARCA:AVDV), Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO